We are live on ! Find out more
CNTX icon

Context Therapeutics

60 hedge funds and large institutions have $195M invested in Context Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 7

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

141% more capital inflows, than outflows

Capital inflows: $57.6M | Capital outflows: $23.9M

40% more funds holding

Funds holding: 43 → 60 (+17)

9.77% more ownership

Funds ownership: 71.07% → 80.84% (+9.8%)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

51% less call options, than puts

Call options by funds: $53K | Put options by funds: $108K

Holders
60
Holders Change
+17
Holders Change %
+39.53%
% of All Funds
0.73%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
25
Increased
10
Reduced
13
Closed
7
Calls
$53​K
Puts
$108​K
Net Calls
-⁠$55​K
Net Calls Change
-⁠$55​K

CNTX Hedge Fund Activity: Q1 2026 in Review

60 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q1 2026, worth a combined $195M — up 103% from $96M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CNTX positions and 7 closed out — a net gain of 18 holders — while 10 added to existing stakes and 13 trimmed.

The largest buyer was Soleus Capital Management, opening a new position worth an estimated $16.3M. The largest seller was Great Point Partners, cutting an estimated $5.71M.

  • 60 institutional investors held Context Therapeutics (CNTX) as of Q1 2026, up from 43 in Q4 2025.
  • Funds reported $195M of Context Therapeutics stock for Q1 2026, up 103% quarter-over-quarter.
  • 25 funds opened new Context Therapeutics positions in Q1 2026 and 7 closed out, a net change of +18 holders.
  • The largest Context Therapeutics buyer in Q1 2026 was Soleus Capital Management, an estimated $16.3M added.
  • The largest Context Therapeutics seller in Q1 2026 was Great Point Partners, an estimated $5.71M sold.

Based on aggregated 13F filings for Q1 2026.